the Treatment of Cardiovascular and Renal Disease"—as well as for all the courtesies and the fine hospitality extended to me during my stay in London.

I also thank you very much for the breakfast meeting of Wednesday, May 10, during which we have had the opportunity to review some questions of mutual interest.

During my stay in London, I greatly enjoyed the privilege of making the acquaintance of Ms. McGraw and of meeting Mr. George McCoy.

Certa's equipment

Under separate cover, I am sending you a second copy of the list and description sheets of the equipment used by Certa in the manufacture of the resin compounds and in the preparation and packaging of Biphetamine-T, Ionamin and Tussionex (liquid and tablets).

This equipment forms part of the manufacturing facilities of Certa, located at Noville-sur-Mehaigne, with 1,600 square meters of floor space (one square meter corresponds to approximately 10 square feet).

The administration as well as the promotion and sales office are located in Brussels (floor space: 470 square meters, together with "Certa International S.A.").

Certa's packages

I hope that you have already received, in good condition the specimen packages of the "Strasenburgh" products, sent by air-parcel post on May 5, 1972.

Regarding the two red stripes on the labels and boxes of Biphetamine, Biphetamine-T and Tussionex, please note that they are compulsory by law; they are the identification mark of preparations containing narcotics and of such products as amphetamines submitted in Belgium to the same restrictions and controls.

Biphetamine

Please communicate to us, at your earliest convenience, your decision concerning the possible supply by Certa to some of your licensees and distributors, of Biphetamine capsules, to be manufactured by us in Belgium according to your specifications and under the very strict control of the Belgian Authorities.

Zaroxolyn agreement

I am awaiting with great interest, the text of the new Zaroxolyn agreement, which—as you told me during our breakfast meeting—is being prepared by your Legal Department.

Furthermore, I was happy to hear that the registration and approval formalities of Zaroxolyn in Great Britain, are being completed according to schedule and that, by June/July, you expect to obtain the approval of the hypotensive claims of Zaroxolyn. It is noted that Zaroxolyn has already been approved as a diuretic, in the U.K.

As agreed, the application for registration in Belgium will be submitted as soon as you obtain the U.K. registration.

Zaroxolyn registration in Belgium

As a first step, the monography on Metolazone substance has already been approved by the Ministry of Health, Brussels, under reference N° G/343/3/71, on March 12, 1971.

A copy of this monography had been sent, in due time, to Strasenburgh International.

In compliance with your request, during my stay in Rochester (March 1972), two copies of the monography and two copies of its approval have been sent to you by Mr. Maurice Renard (his letter of March 23, 1972).

The registration "dossier" of Zaroxolyn for Belgium is ready, on the basis of the data and papers received from your end. We suggest and will be happy to submit to you, for approval, a full photostatic copy of this file. I will welcome your comments.

Sales of diuretics etc. in Belgium

Regarding the sales of diuretics in Belgium, as well as those of hypotensive agents, I handed over to you the statistics of the 4th quarter of 1971, with recapitulative totals for the whole year and a comparison (±%) with 1970.

The quantities (units) and the values mentioned in these statistics must be multiplied by 100.